Anti-PI-3 kinase p110α Antibody, clone 1J4 ZooMAb® Rabbit Monoclonal

Description

• General description: We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
• Specificity: Clone 1J4 is a ZooMAb® Rabbit recombinant monoclonal antibody that specifically detects PI-3 kinase p110a. It targets an epitope within 24 amino acids from the internal region.
• Immunogen: KLH-conjugated linear peptide corresponding to 24 amino acids from the internal region of human PI-3 kinase p110a.
• Application: Quality Control TestingEvaluated by Western Blotting in HeLa cell lysate.Western Blotting Analysis: A 1:10,000 dilution of this antibody detected PI-3 kinase p110a in HeLa cell lysate.Tested applicationsWestern Blotting Analysis: A 1:10,000 dilution from a representative lot detected PI-3 kinase p110a in K562 cell lysate.Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected PI-3 kinase p110 in human cerebellum and human kidney tissue sections.Affinity Binding Assay: A representative lot of this antibody bound PI3 Kinase p110 with a KD of 6.6 x 10-7 in an affinity binding assay.Flow Cytometry Analysis: 1 μg from a representative lot detected PI-3 kinase p110 in one million K562 cells.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
• Target description: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (UniProt: P42336; also known as EC:2.7.1.137, PI3-kinase subunit alpha, PI3K-alpha, PI3Kalpha, PtdIns-3-kinase subunit alpha, Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha, PtdIns-3-kinase subunit p110-alpha, p110alpha, Phosphoinositide 3-kinase alpha, Phosphoinositide-3-kinase catalytic alpha polypeptide, Serine/threonine protein kinase PIK3CA) is encoded by the PIK3CA gene (Gene ID: 5290) in human. The PI 3-kinases (PI3-K) are ubiquitous, heterodimeric enzymes that play a crucial role in the regulation of many cellular processes, including cell growth, proliferation, motility, and survival. They are divided into three classes based on their structure and substrate specificity. Class I PI 3-K contain a 110 kDa catalytic subunit and an 85 kDa regulatory subunit. The catalytic subunit associates with an 85 kDa adaptor/regulatory subunit that is essential for interaction of these PI3-K with receptor tyrosine kinases and intracellular proteins. Following ligand binding to receptor and activation of receptor tyrosine kinase, the p85/p110 complex is recruited to the receptor by interaction of the SH2 domain of p85 with consensus phosphotyrosine residues on receptor tyrosine kinase. The interaction of a receptor tyrosine kinase with the p85 subunit relieves the inhibitory effect of p85 on the p110 catalytic subunit and the activated PI3-K phosphorylates phosphoinositol (PI) substrates to produce PIP, PIP2, and PIP3. These molecules act as second messengers for downstream signal transduction. Class IA PI3-K signal transduction is considered to be important in mediating insulin responses in cells. Any loss in the activity of these kinases can result in metabolic defects linked to type 2 diabetes. Inhibition of PI 3-kinase and overexpression of dominant negative PI3-K mutants are shown to block many of the physiological responses to insulin. Overactivation of PI3-K pathway can perturb the control mechanisms for cell growth and survival and contribute to metastatic competence and resistance to chemotherapy. Abnormal activation of PI3-K is seen in several forms of cancer. About 30% of solid tumors contain mutations in the catalytic unit of their PI3-K, which increase its enzymatic activity and produce excessive Akt signal transduction. This ZooMAbZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.
• Physical form: Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
• Reconstitution: 300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
• Storage and Stability: Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
• Legal Information: ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.